Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial

Vir Biotechnology, Inc.

De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.
Tobevibart monotherapy: 55% (6/11) combined endpoint at week 24.
No serious adverse events, no ALT flares; majority of AEs Grade 1-2 and transient.
Company to report additional 24-week data for all ~60 participants in Q4 2024.
Data to be presented at EASL Congress on June 8, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.